The role of p95HER2 in trastuzumab resistance in breast cancer

ELİYATKIN N. Ö., AKTAŞ S., Ozgur H., Ercetin P., Kupelioglu A.

JOURNAL OF BUON, vol.21, no.2, pp.382-389, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 2
  • Publication Date: 2016
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.382-389
  • Keywords: breast cancer, p95HER2, trastuzumab resistance, HER2, AMPLIFICATION, MECHANISMS, EXPRESSION, EFFICACY, RECEPTOR, GROWTH, SAFETY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Purpose: Trastuzumab, the HER2 oncogene targeting drug, shows remarkable clinical efficacy in HER2-amplified breast cancer patients. Despite of robust activity, some of the patients with HER2-positive breast cancers do not get the benefit due to trastuzumab resistance. Overexpression of p95HER2 is one of the molecular mechanisms of trastuzumab resistance. The purpose of this study was to investigate whether p95HER2 overexpressing breast cancers were resistant to trastuzumab.